Discovery and development of new-generation polymyxins against Gram-negative 'superbugs'

This project aims to employ novel approaches to discover new-generation polymyxin antibiotics targeting the deadly Gram-negative ‘superbugs’. Novel lead molecules have been licensed to Qpex Biopharma (US) for IND-enabling evaluations with a Phase-I study aimed at 2020.

Lead organisation(s):

Monash University and I (Jian Li, Professor, PhD) am the principal investigator. My project is currently funded by the American National Institutes of Health (NIH).

Project type:
Research
Status:
In progress
Timeframe:
This program originally started in 2009 and will continue for at least another 4 years.
Tags:
For more information on this research or activity:
Monash Qpex polymyxin articles

Learn more at US biopharmaceutical company licenses Monash University 'superbug' drug discovery.

 

Edits to this research are currently being reviewed. If you want to update or request removal please email amr.website@health.gov.au.

Last updated:

Help us improve our website

If you would like a response please use the Feedback form instead.